Medicine and Dentistry
Age
5%
Anticarcinogen
7%
Body Weight
7%
Bone Metastasis
6%
Breast Cancer
12%
Cancer Staging
5%
Carboplatin
10%
Cervical Cancer
5%
Cisplatin
22%
Clinical Feature
6%
Diagnosis
14%
Epidermal Growth Factor Receptor
5%
Follow up
7%
Ganglioglioma
13%
Gemcitabine
36%
Glioblastoma
10%
Immune Checkpoint Inhibitor
17%
Inpatient
18%
Isocitrate Dehydrogenase
17%
Liver Metastasis
9%
Logistic Regression Analysis
5%
Lung Cancer
9%
Macrophage
5%
Male
9%
Malignant Neoplasm
15%
Neoplasm
23%
Neutrophil
10%
Non Small Cell Lung Cancer
32%
Nutrient Intake
5%
Nutritional Support
5%
Odds Ratio
12%
Overall Survival
42%
Patient
100%
Patient with Cancer
6%
Pembrolizumab
9%
Prognostic Factor
8%
Progression Free Survival
11%
Proportional Hazards Model
11%
Protein
6%
Protein Intake
14%
Recurrence Free Survival
8%
Regression Analysis
5%
Sex
7%
Skeletal Muscle
21%
Survival
29%
Therapeutic Procedure
75%
Toxicity
6%
Nursing and Health Professions
Anticarcinogen
7%
Body Composition
14%
Breast Cancer
12%
Carboplatin
8%
Chemotherapy
8%
Cisplatin
19%
Compliance
8%
Confidence Interval
20%
Control
7%
Dose
5%
Gemcitabine
32%
Inpatient
18%
Lung Cancer
9%
Malignant Neoplasm
10%
Malnutrition
9%
Non Small Cell Lung Cancer
13%
Odds Ratio
12%
Overall Survival
26%
Patient
51%
Pembrolizumab
7%
Procedures
5%
Progression Free Survival
7%
Quality of Life
6%
Survival
7%
Toxicity
6%
Weight
14%
Woman
14%
Pharmacology, Toxicology and Pharmaceutical Science
Anticarcinogen
7%
Bone Metastasis
6%
Breast Cancer
12%
Carboplatin
10%
Cisplatin
22%
Clinical Feature
6%
Clinical Trial
8%
Comorbidity
6%
Epidermal Growth Factor Receptor
5%
Gemcitabine
36%
Glioblastoma
10%
Glioma
13%
Immune Checkpoint Inhibitor
34%
Liver Metastasis
9%
Malignant Neoplasm
12%
Neoplasm
15%
Non Small Cell Lung Cancer
22%
Overall Survival
40%
Pembrolizumab
9%
Progression Free Survival
11%
Randomized Controlled Trial
12%
Survival
27%
Toxicity
6%